Liquidia vs Mirum Pharmaceuticals
LQDA and MIRM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LQDA and MIRM compare
Mirum Pharmaceuticals is the larger company, worth 1.2 times as much as Liquidia ($6.0B against $5.1B).
Liquidia grew revenue faster over the last twelve months (2234% versus 44.0% for Mirum Pharmaceuticals).
Liquidia keeps more of each dollar of sales as profit, with a net margin of 30.7% compared with −139% at Mirum Pharmaceuticals.
Liquidia scores higher on the StockData Score (8 against 5 for Mirum Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LQDA | MIRM |
|---|---|---|
| Size and price | ||
| Market cap | $5.1B | $6.0B |
| Share price | $56.73 | $91.95 |
| Change, 1 year | 102% | 28.7% |
| Change, 5 years | 1280% | 586% |
| Beta (5Y) | 1.00 | 0.61 |
| Employees | 216 | 372 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 40.8× | – |
| P/S | 11.3× | 9.7× (better) |
| P/B | 26.0× | – |
| EV/EBITDA | 28.2× | – |
| P/FCF | 33.7× | – |
| FCF yield | 3.0% (better) | −3.8% |
| Fair value | $32.46 | – |
| Margin of safety | −74.8% | – |
| Growth | ||
| Revenue growth (TTM) | 2234% (better) | 44.0% |
| Revenue growth, 5Y average | 192% | – |
| Profitability | ||
| Operating margin | 37.4% (better) | −135% |
| Net margin | 30.7% (better) | −139% |
| FCF margin | 33.4% (better) | −37.0% |
| Return on equity | 132% (better) | −703% |
| Financial health | ||
| Interest coverage | 6.3× (better) | −62.1× |
| Current ratio | 2.31 | 2.86 (better) |
| Altman Z-score | 10.49 (better) | −0.22 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 81.1% | 110% |
| Held by insiders | 19.5% | 9.2% |
| Insider net buying, 12 months | −$227M | −$32.8M (better) |
| Short interest, % of float | 24.3% | 11.1% |
Go deeper
- LQDA stock overview
- LQDA income statement
- LQDA valuation and score
- MIRM stock overview
- MIRM income statement
- MIRM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.